Compare LARK & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LARK | NGEN |
|---|---|---|
| Founded | 1885 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.0M | 197.5M |
| IPO Year | 2001 | N/A |
| Metric | LARK | NGEN |
|---|---|---|
| Price | $30.75 | $1.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 12.2K | ★ 893.1K |
| Earning Date | 04-29-2026 | 04-02-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 35.84 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $36.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.57 | $1.70 |
| 52 Week High | $30.80 | $5.93 |
| Indicator | LARK | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 77.35 | 34.21 |
| Support Level | $25.46 | $1.70 |
| Resistance Level | N/A | $4.44 |
| Average True Range (ATR) | 0.72 | 0.17 |
| MACD | 0.18 | 0.06 |
| Stochastic Oscillator | 100.00 | 25.19 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.